Large population case-control studies with 10 years of follow-up improved the understanding of the association between CHIP and AML [65,66]; mutations in genes such as TP53, IDH1, and IDH2 demonstrated increased specificity and penetrance for the development of AML. The gene discussed is IDH2; the disease is acute myeloid leukemia.